Active Biotech purchases recently launched Gyrolab Bioaffy

25-Nov-2003

Gyros AB announced that Active Biotech AB is the first company to purchase Gyrolab Bioaffy(TM), a solution for protein quantification in which single or multiplex immunoassays are performed at nanoliter scale in CD microlaboratories. Tomas Leanderson, Chief Scientific Officer at Active Biotech explained "Our first impression is that this approach to miniaturization and integration of immunoassays could give us significant gains in productivity compared to our traditional way of working."

Leanderson continued, "As a biotechnology company focusing on research and development of pharmaceuticals, it is essential that we exploit the most efficient tools available in the market."

Per Sjöberg, Executive Vice President Marketing and Sales, Gyros AB added, "We are extremely pleased that Active Biotech recognizes the value of Gyros technology platform, especially the recently launched Gyrolab Bioaffy. To receive our first order so quickly after commercial introduction in August this year makes us confident that we are on the right track with our product development strategy. We focus on areas in which working in a CD microlaboratory format has clear advantages. Gyrolab Bioaffy allows scientists to assay their proteins under conditions optimized for handling small volumes and many samples. Working at nanoliter scale gives a major reduction in sample and reagent consumption per data point. Since more proteins can be assayed in a single sample, many time-consuming and costly investigations caused by limited sample availability, such as biomarker profiling in small animal models, can be reduced to days rather than weeks."

https://www.bionity.com/en/news/32066/active-biotech-purchases-recently-launched-gyrolab-bioaffy.html